Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.
Market Dynamics
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.
Key features of the study:
- This report provides an in-depth analysis of the global cholangiocarcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cholangiocarcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market
Detailed Segmentation:
- Global Cholangiocarcinoma Market, By Treatment Type:
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- Global Cholangiocarcinoma Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Cholangiocarcinoma Market, By Region:
- North America
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- , By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Incyte Corporation*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- QED Therapeutics, Inc.
- Agios Pharmaceuticals, Inc.
- RenovoRx
- Ability Pharmaceuticals
- Imbrium Therapeutics L.P.
- Delcath Systems, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
